MAPK3 and cancer: Inhibition of ERK1/2 signalling with MEK inhibitors resulted in the rapid loss of Ser592 phosphorylation and an increase in mitochondrial fusion, which was also observed in human cancer lines with oncogenic BRAFV600E mutations.